Hebei Shanghai Trading Co., Ltd CAS number 1048973-47-2



About

Good quality and low price Factory supply Procaine N\'-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazide MDA-19 99.8% Yellow powder MF Hebei Shanghai Trading Co., Ltd CAS number 1048973-47-2


More Detail

<p>Common NameMDA-19CAS Number<a href=\"https://www.chemsrc.com/en/baike/452287.html\" target=\"_blank\">1048973-47-2</a>Molecular Weight349.426Density1.2&plusmn;0.1 g/cm3Boiling PointN/AMolecular FormulaC21H23N3O2Melting PointN/AMSDSN/AFlash PointN/A</p> <p><em>&nbsp;</em>Use of MDA-19</p> <p><br /> MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3&#39;,5&#39;-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.</p> <p>Names</p> <p>NameN&#39;-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazideSynonym<a href=\"https://www.chemsrc.com/en/cas/1048973-47-2_452287.html#ebiemingDiv\">More Synonyms</a></p> <p><em>&nbsp;</em>MDA-19 Biological Activity</p> <p>DescriptionMDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3&#39;,5&#39;-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.Related Catalog</p> <p><a href=\"https://www.chemsrc.com/en/CatgBio/3519.html\">Signaling Pathways</a> &gt;&gt; <a href=\"https://www.chemsrc.com/en/CatgBio/3627.html\">GPCR/G Protein</a> &gt;&gt; <a href=\"https://www.chemsrc.com/en/CatgBio/3636.html\">Cannabinoid Receptor</a></p> <p><a href=\"https://www.chemsrc.com/en/CatgBio/3520.html\">Research Areas</a> &gt;&gt; <a href=\"https://www.chemsrc.com/en/CatgBio/3942.html\">Neurological Disease</a></p> <p>Solvent</p> <p>In Vitro:</p> <p><strong>DMSO : 14.29 mg/mL (40.90 mM; Need ultrasonic)</strong></p> <p><strong>H2O : &lt; 0.1 mg/mL (insoluble)</strong></p> <p>In Vivo: 1.Add each solvent one by one: &nbsp;10% DMSO &nbsp;&nbsp; 90% corn oil Solubility: &ge; 1.43 mg/mL (4.09 mM); Clear solution 2.Add each solvent one by one: &nbsp;10% DMSO &nbsp;&nbsp; 90% (20% SBE-&beta;-CD in saline) Solubility: 1.43 mg/mL (4.09 mM); Suspended solution; Need ultrasonicSolubility1 mM2.8618 mL14.3090 mL28.6180 mL5 mM0.5724 mL2.8618 mL5.7236 mL10 mM0.2862 mL1.4309 mL2.8618 mLStoragePowder-20&deg;C3 years&nbsp;4&deg;C2 yearsIn solvent-80&deg;C6 months&nbsp;-20&deg;C1 monthShippingRoom temperature in continental US; may vary elsewhereSMILESO=C(N/N=C1C(N(CCCCCC)C2=C\\1C=CC=C2)=O)C3=CC=CC=C3References</p> <p>[1]. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18666769\" target=\"_blank\">Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemi</a></p> <p>[2]. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20522703\" target=\"_blank\">Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109.</a></p> <p>Related Molecules<a href=\"https://www.chemsrc.com/en/cas/131543-23-2_906266.html\" target=\"_blank\">WIN 55212-2 mesylate</a> | <a href=\"https://www.chemsrc.com/en/cas/183232-66-8_587378.html\" target=\"_blank\">AM251</a> | <a href=\"https://www.chemsrc.com/en/cas/701977-09-5_332501.html\" target=\"_blank\">Taranabant</a> | <a href=\"https://www.chemsrc.com/en/cas/192703-06-3_452767.html\" target=\"_blank\">SR144528</a> | <a href=\"https://www.chemsrc.com/en/cas/406205-74-1_1105000.html\" target=\"_blank\">Bay 59-3074</a> | <a href=\"https://www.chemsrc.com/en/cas/868273-06-7_754236.html\" target=\"_blank\">Org 27569</a> | <a href=\"https://www.chemsrc.com/en/cas/686344-29-6_981813.html\" target=\"_blank\">Otenabant</a> | <a href=\"https://www.chemsrc.com/en/cas/666260-75-9_425888.html\" target=\"_blank\">GW842166X</a> | <a href=\"https://www.chemsrc.com/en/cas/959746-77-1_964993.html\" target=\"_blank\">A-836339</a> | <a href=\"https://www.chemsrc.com/en/cas/2854-32-2_671808.html\" target=\"_blank\">BML-190</a> | <a href=\"https://www.chemsrc.com/en/cas/1392116-14-1_1466362.html\" target=\"_blank\">JD-5037</a> | <a href=\"https://www.chemsrc.com/en/cas/362519-49-1_906403.html\" target=\"_blank\">(&plusmn;)-SLV319</a> | <a href=\"https://www.chemsrc.com/en/cas/145-13-1_895855.html\" target=\"_blank\">Pregnenolone</a> | <a href=\"https://www.chemsrc.com/en/cas/94421-68-8_753820.html\" target=\"_blank\">Anandamide</a> | <a href=\"https://www.chemsrc.com/en/cas/53847-30-6_166491.html\" target=\"_blank\">2-arachidonoylglycerol</a></p> <p><em>&nbsp;</em>Chemical &amp; Physical Properties</p> <p>Density1.2&plusmn;0.1 g/cm3Molecular FormulaC21H23N3O2Molecular Weight349.426Exact Mass349.179016PSA61.77000LogP4.99Index of Refraction1.607</p> <p><em>&nbsp;</em>Safety Information</p> <p>HS Code2933790090</p> <p><em>&nbsp;</em>Synthetic Route</p> <p>Total: 1 Page</p> <p>&nbsp;</p> <p><a href=\"https://www.chemsrc.com/en/cas/56932-61-7_234062.html\" target=\"_blank\">N-(n-hexyl)indo...</a></p> <p>&nbsp;</p> <p><a href=\"https://www.chemsrc.com/en/cas/56932-61-7_234062.html\" target=\"_blank\">CAS#:56932-61-7</a></p> <p>&nbsp;</p> <p><a href=\"https://www.chemsrc.com/en/cas/613-94-5_325177.html\" target=\"_blank\">Benzohydrazide</a></p> <p>&nbsp;</p> <p><a href=\"https://www.chemsrc.com/en/cas/613-94-5_325177.html\" target=\"_blank\">CAS#:613-94-5</a></p> <p>&nbsp;</p> <p>~78%</p> <p>MDA-19</p> <p>CAS#:1048973-47-2</p> <p>Literature: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Patent: WO2009/12227 A1, 2009 ; Location in patent: Page/Page column 55-56 ; WO 2009/012227 A1</p> <p><em>&nbsp;</em>Precursor &amp; DownStream</p> <p>Precursor&nbsp; 2</p> <p>&nbsp;</p> <ul> <li><a href=\"https://www.chemsrc.com/en/cas/56932-61-7_234062.html\" target=\"_blank\">CAS#:56932-61-7<br /> N-(n-hexyl)indo...</a></li> <li><a href=\"https://www.chemsrc.com/en/cas/613-94-5_325177.html\" target=\"_blank\">CAS#:613-94-5<br /> Benzohydrazide</a></li> </ul> <p>DownStream&nbsp; 0</p> <p>&nbsp;</p> <p><em>&nbsp;</em>Customs</p> <p>HS Code2933790090Summary2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0%</p> <p><em>&nbsp;</em>Synonyms</p> <p>1,2,4-Triazine-6-carboxaldehyde,2,3,4,5-tetrahydro-3,5-dioxoO-benzylfluorescein benzyl esterdibenzylfluoresceinO,O&#39;-DibenzylfluoresceinMDA-19N&#39;-[(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazideBenzoic acid, 2-[(3Z)-1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene]hydrazideMDA 19</p> <p>Use of MDA-19</p> <p><br /> MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3&#39;,5&#39;-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.</p>


Reviews



People Also Like

See More

10 Days Weather forecast of 石家庄市, 中国

Croozi has eased your travel plan more by providing weather forecast of 10 days for that location, all at one place. Now you don't have to go through so many websites to plan a single journey. You are welcome!

Why Croozi?

There are many different ways to market your business or service. The most important thing is to make sure that you are reaching your target audience. In order to list down your business, you'll need to market your business and services. You can do this by creating a website or blog and writing about your business that provides all the information that potential customers might be looking for.. You can also list your business in online directories. Make sure to include all of the relevant information about your business, such as your contact information, hours of operation, and location.

There are a few things to keep in mind when marketing your business or service. First, you need to make sure that you list your business in the right directories and the best way to boost your business online is to save your business on croozi.com a website that is user-friendly and more informative for your business with more than 10 Million users. Make sure to include relevant keywords so that your site comes up in search engine results. and potential customers can easily find you when they’re looking for products or services in your industry. This means making sure that your business is easy to find and navigate. Croozi will help you to interact with your followers and build relationships with other businesses in your industry.